Skip to main content
. Author manuscript; available in PMC: 2014 Apr 9.
Published in final edited form as: Int J Tuberc Lung Dis. 2013 Feb 7;17(4):486–492. doi: 10.5588/ijtld.12.0133

Table 1.

Baseline demographic and clinical characteristics of the study population

Characteristic Persons who took
>12 months to
complete treatment
(n = 261)
n (%)
Persons who took
<12 months to
complete treatment
(n = 2366)
n (%)
P value*
Age at report date, years, median [IQR] 44 [31–59] 45 [30–61] 1.00
Male sex 184 (70.5) 1552 (65.6) 0.11
Black, non-Hispanic race 133 (51.0) 978 (41.3) 0.004
US-born 217 (83.1) 1769 (79) 0.002
Homeless 30 (11.5) 205 (8.7) 0.14
Correctional facility 21 (8.0) 102 (4.3) 0.01
Long-term care facility 7 (2.7) 55 (2.3) 0.67
HIV infection 31 (11.9) 194 (8.2) 0.04
Alcohol use 67 (25.7) 453 (19.1) 0.01
IDU 5 (1.9) 41 (1.7) 0.80
Non-IDU 36 (13.8) 263 (11.1) 0.22
Extra-pulmonary disease 73 (28.0) 510 (21.6) 0.02
Cavitary disease 92 (35.2) 639 (27.0) 0.006
Smear-positive 181 (69.3) 1157 (48.9) <0.0001
Culture-positive 225 (86.2) 1710 (72.3) <0.0001
Type of treatment
  Exclusively DOT 154 (59.0) 1632 (69.0) 0.001
  DOT/SAT combination 91 (34.5) 667 (28.2) 0.03
  Exclusively SAT 10 (3.8) 46 (1.9) 0.06
Subsequent TB recurrence 4 (1.5) 22 (0.9) 0.32
Time to completion of treatment, weeks, median [IQR] 58.7 [53.8–70.0] 29.8 [26.6–39.6] <0.0001
*

Fisher’s exact and Wilcoxon’s rank sum tests were used to compare categorical and continuous variables, respectively.

IQR = interquartile range; HIV = human immunodeficiency virus; IDU = injection drug use; DOT = directly observed therapy; SAT = self-administered therapy.